Jpmorgan Chase & CO Arca Biopharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABIO
# of Institutions
35Shares Held
12.9MCall Options Held
41.6KPut Options Held
5.6K-
Cable Car Capital LLC San Francisco, CA4MShares$016.14% of portfolio
-
Rtw Investments, LP New York, NY1.4MShares$00.09% of portfolio
-
Janus Henderson Group PLC London, X01.38MShares$00.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.2MShares$00.01% of portfolio
-
Avidity Partners Management LP Dallas, TX1MShares$00.19% of portfolio
About ARCA biopharma, Inc.
- Ticker ABIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,410,100
- Description
- ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...